Chen, P.,
Yu, Y.,
Su, S.,
Du, Z.,
Cai, B.,
Sun, X.,
Chattipakorn, N.,
Samorodov, A.V.,
Pavlov, V.N.,
Tang, Q.,
Cho, W.-J.,
Liang, G. (2023) %–40%. There is an unmet
clinical need owing to limited
treatment strategies and little clinical benefit. The pathology
Nasyrova, Regina F,
Vaiman, Elena E,
Repkina, Vera V,
Khasanova, Aiperi K,
Asadullin, Azat R,
Shipulin, German A,
Altynbekov, Kuanysh S,
Al-Zamil, Mustafa,
Petrova, Marina M,
Shnayder, Natalia A (2023) strategy for the personalized prevention and
treatment of this adverse neurological drug reaction of APs
. It was revealed that strain OBA 2.4.1 is tolerant of up to 2 mM CdCl2, and seed
treatment with the bacterium
Ivanova, Elizaveta,
Asadullina, Dilara,
Gilyazova, Gulshat,
Rakhimov, Radmir,
Izmailov, Adel,
Pavlov, Valentin,
Khusnutdinova, Elza,
Gilyazova, Irina (2023) renal cell carcinoma (ccRCC)
treatment. However, the response to therapy among patients
varies greatly
Evdakov, V.A.,
Starodubov, V.I.,
Oleynik, B.A.,
Sharafutdinova, N.Kh.,
Borisova, M.V.,
Plechev, V.V. (2023) phases
treatment. These positive effects have led to significant increase in the prevalence of patients